When AI saves lives: iCAD's FDA-cleared imaging solution & the Future of Healthcare
Listen to Codrin Arsene interview Michael Klein, the CEO @ iCAD, one of the few FDA-approved artificial intelligence solutions for radiologists. iCAD's AI analyzes hundreds of data-points to deliver powerful software solutions for breast tomosynthesis, breast density and 2D mammography. In simple terms, the iCAD software (Profound AI) analyzes mammogram images and correlates them to demographic data to produce cancer probability scores for radiologists. Whereas iCAD cannot officially 'diagnose' breast cancer, the software alerts radiologists of any abnormalities tied to mammogram images for further inspection. In the clinical trial which led to iCAD getting FDA approval, Profound AI was responsible for detecting 8% more cancers than the group of radiologists that analyzed the same data set. Listen to the podcast to learn about the history of iCAD, their current AI solution, new exciting features and functionalities iCAD plans to release later this year and the future of AI in healthcare.